Health ❯ Mental Health ❯ Depression

Treatment-Resistant Depression

Clinical Trials Ketamine Ketamine Therapy Psychedelic Therapy Ketogenic Diet Esketamine Music Therapy Neuroplastogens Nasal Spray Treatment Spravato Ketamine Research SPRAVATO Psilocybin Treatment Ketamine Addiction Ketamine Risks Neuroplasticity Nitrous Oxide Nitrous Oxide Treatment Nerve Stimulation Therapy Clinical Research Patient Experiences Nasal Spray Treatments Brain Implant Technology Psilocybin Immunotherapy

Lilly to Acquire AtaiBeckley in Deal Valued Up to $3.8 Billion

The purchase puts a Breakthrough‑designated intranasal 5‑MeO‑DMT into Lilly's neuroscience portfolio, potentially speeding its development.

IL‑6 Blocker Tocilizumab Shows Early Promise for Inflammation‑Linked Depression

FDA Clears Motif Neurotech Trial of At-Home Brain Implant for Treatment-Resistant Depression

Psilocybin Therapy Clears Second Phase 3 Test as Compass Pathways Preps FDA Bid

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

Small Trial Finds Short-Term Antidepressant Effect From Ketogenic Diet in Treatment-Resistant Depression

Meta-Analysis Finds Nitrous Oxide Offers Rapid, Short-Lived Relief for Depression

IV Ketamine Shows Faster, Larger Gains Than Esketamine Nasal Spray in New Real‑World Depression Study